Journal of Vascular and Interventional Radiology
Volume 21, Issue 3 , Pages 333-338 , March 2010

Chemoembolization with Lobaplatin Mixed with Iodized Oil for Unresectable Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation

  • Bin Zhou, MD

      Affiliations

    • Department of Radiology, Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou 510630, China
    • ,
  • Hong Shan, MD

      Affiliations

    • Department of Radiology, Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou 510630, China
    • Corresponding Author InformationAddress correspondence to H. S.
    • ,
  • Kang-Shun Zhu, MD

      Affiliations

    • Department of Radiology, Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou 510630, China
    • ,
  • Zai-Bo Jiang, MD

      Affiliations

    • Department of Radiology, Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou 510630, China
    • ,
  • Shou-Hai Guan, MD

      Affiliations

    • Department of Radiology, Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou 510630, China
    • ,
  • Xiao-Chun Meng, MD

      Affiliations

    • Department of Radiology, Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou 510630, China
    • ,
  • Xian-Cheng Zeng, MD

      Affiliations

    • Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Rd, Guangzhou 510630, China

Received 14 February 2009 ,Revised 3 November 2009 ,Accepted 9 November 2009.

References 

  1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–543
  2. Regalia E, Fassati LR, Valente U, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg. 1998;5:29–34
  3. Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?. Transplantation. 2002;74:1746–1751
  4. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534–540
  5. Island ER, Pomposelli J, Pomfret EA, et al. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg. 2005;140:353–358
  6. Bernal E, Montero JL, Delgado M, et al. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc. 2006;38:2495–2498
  7. Söderdahl G, Bäckman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int. 2006;19:288–294
  8. Brown DB, Gould JE, Gervais DA, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2007;18:1469–1478
  9. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg. 2002;235:533–539
  10. Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation. 2005;80:S113–S119
  11. Alba E, Valls C, Dominguez J, et al. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am J Roentgenol. 2008;190:1341–1348
  12. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12:1260–1267
  13. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;13:272–279
  14. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502–509
  15. McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001;10:119–128
  16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guideline to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205–216
  17. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27:446–452
  18. Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. Liver Transpl. 2005;43:584–589
  19. Shiina S. Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol. 2009;44(Suppl 19):122–131
  20. Orlando A, Leandro G, Olivo M, et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2009;104:514–524
  21. Stuart K. Chemoembolization in the management of liver tumors. Oncologist. 2003;8:425–437
  22. Ko HK, Ko GY, Yoon HK, Sung KB. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol. 2007;8:320–327
  23. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442
  24. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:S179–S188
  25. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2003;97:1042–1050

 This study was supported by the Team Project of Natural Science Foundation of Guangdong Province (5200177).

 None of the authors have identified a conflict of interest.

PII: S1051-0443(09)01138-5

doi: 10.1016/j.jvir.2009.11.006

Journal of Vascular and Interventional Radiology
Volume 21, Issue 3 , Pages 333-338 , March 2010

Article Tools

* Image Usage & Resolution